阿立哌唑与认知行为联合应用于首发精神分裂症患者对认知功能的改善作用
[摘要] 目的 为有效改善精神分裂症患者认知功能，探讨阿立哌唑、认知行为联合应用治疗对患者认知功能的改善效果。 方法 本次研究对象为2013年7月～2014年9月期间我院收治的70例首发精神分裂症患者，按照病床单双号分为药物对照组35例、观察组35例。药物对照组口服阿立哌唑，观察组在此基础上进行认知行为干预，观察两组患者治疗效果。 结果 观察组精神恢复有效率为94.3%较对照组80.0%好，观察组患者疾病症状、认知能力改善程度较对照组好（P<0.05）；治疗前两组PANSS、SDSS评分比较差异无统计学意义（P>0.05），治疗后观察组较对照组疗效好（P<0.05）。 结论 临床对精神分裂首发患者采用阿立哌唑、认知行为联合应用治疗疾病，患者认知功能改善效果明显。
[关键词]首发精神分裂症；认知行为；阿立哌唑；认知能力
[中图分类号] R749.3 [文献标识码] B [文章编号] 2095-0616（2017）15-230-03
[Abstract] Objective To improve the cognitive function of patients with schizophrenia， to explore the effect of combined treatment of aripiprazole and cognitive behavior on cognitive function of patients. Methods 70 patients with first-episode schizophrenia cured in our hospial from july 2013 to September 2014 were selected. According to the bed number and even number， they were divided into medicine control group and observation group with 35 cases in each. Patients in medicine control group were treated with oral aripiprazole， and patients in observation group were treated with cognitive behavioral intervention on the basis of control group. The treatment effects of the two groups were compared. Results The effective rate of mental recovery in observation group was 94.3%， which was better than that of control group with 80.0%. The improvement of disease symptoms and cognitive ability in the observation group was better than that in the control group （P<0.05）. Before treatment， there was no significant difference in PANSS and SDSS scores betw...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
